Arthur Kuan, born on May 1, 1978, is the CEO and Chairman of CG Oncology. He has a strong background in business, with an MBA from Harvard Business School and previous roles at major investment firms, which helped shape his...

Arthur Kuan, born on May 1, 1978, is the CEO and Chairman of CG Oncology. He has a strong background in business, with an MBA from Harvard Business School and previous roles at major investment firms, which helped shape his strategic insight in the healthcare sector. He started CG Oncology in 2017 and has led the company through its initial public offering, focusing on innovative cancer treatment solutions. Notably, he has played a key role in establishing CG Oncology’s partnerships with Asian markets to expand their reach. Arthur’s leadership is reflected in his solid financial strategy that includes effective resource allocation and performance-oriented compensation philosophy for executives. In 2022, he earned a total compensation of $535,130, which included a performance-based bonus, indicating a strong alignment of his interests with company performance goals. Arthur's commitment to transparency and accountability is evident in his active involvement in corporate governance and his dedication to advancing cancer therapies on a global scale.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

C

Arthur Kuan

CEO of CG Oncology

Education

MBA from Harvard Business School

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

May 15, 1984 - 41 years ago

CEO of CG Oncology for

3 years 5 months (Jan 2022 - Present)

Previous Experience

CEO of a biotech startup

Rivals

Competitors/colleagues of Arthur Kuan

Holdings

See how much did Arthur Kuan make over time.

As of early 2024, Arthur Kuan has 308,508 shares of CG Oncology and significant options. He has seen fluctuations in his holdings, particularly with options vesting over four years linked to company performance milestones. His options include a notable grant...

As of early 2024, Arthur Kuan has 308,508 shares of CG Oncology and significant options. He has seen fluctuations in his holdings, particularly with options vesting over four years linked to company performance milestones. His options include a notable grant of 524,383 shares at an exercise price of $6.67, reflecting the company's growth trajectory. In his early tenure, the value of options spiked, aligning his wealth closely with CG Oncology's success. These holdings show a commitment to the company’s future and align his interests with those of shareholders.

Insider Trading

See recent insider trades of Arthur Kuan.

No insider trades found for this CEO.

Compensation History

See how much did Arthur Kuan make over time.

In 2022, Arthur Kuan's total compensation was $535,130, which included a base salary of $394,000 and a performance bonus of $140,000. His compensation is designed to align with performance metrics set by the board, incentivizing success. Importantly, no stock or options vested in 2022, which reflects a corporate aim to tie rewards directly to company performance. For 2023, he was eligible for a bonus structure that emphasizes achieving corporate goals, which mirrors his approach of constantly pushing for high standards and accountability within the company. As CG Oncology grows, Arthur's compensation framework seems keenly positioned to foster excellence and strategic growth.

Year

2022

Total Compensation

$535.13K

Salary

$394.00K

Board Justification

The company aims to align CEO compensation with performance metrics and market benchmarks to retain top talent and drive company success.

Bonus

$140.00K

Board Justification

Performance bonus earned in 2022, paid in early 2023

Other

$1.13K

Board Justification

401(k) matching contributions and company-paid premiums for long-term disability and life insurance

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock vested in 2022

Performance Metrics

Performance metrics are based on corporate goals established by the board of directors.